RESUMO
The design of drugs with selective tissue distribution can be an effective strategy for enhancing efficacy and safety, but understanding the translation of preclinical tissue distribution data to the clinic remains an important challenge. As part of a discovery program to identify next generation liver selective HMG-CoA reductase inhibitors we report the identification of (3R,5R)-7-(4-((3-fluorobenzyl)carbamoyl)-5-cyclopropyl-2-(4-fluorophenyl)-1H-imidazol-1-yl)-3,5-dihydroxyheptanoic acid (26) as a candidate for treating hypercholesterlemia. Clinical evaluation of 26 (PF-03491165), as well as the previously reported 2 (PF-03052334), provided an opportunity for a case study comparison of the preclinical and clinical pharmacokinetics as well as pharmacodynamics of tissue targeted HMG-CoA reductase inhibitors.
Assuntos
Descoberta de Drogas , Ácidos Heptanoicos/síntese química , Inibidores de Hidroximetilglutaril-CoA Redutases/síntese química , Hipercolesterolemia/tratamento farmacológico , Imidazóis/síntese química , Fígado/efeitos dos fármacos , Animais , Células Cultivadas , Cães , Relação Dose-Resposta a Droga , Hepatócitos/efeitos dos fármacos , Ácidos Heptanoicos/química , Ácidos Heptanoicos/farmacocinética , Ácidos Heptanoicos/farmacologia , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Imidazóis/química , Imidazóis/farmacocinética , Imidazóis/farmacologia , Concentração Inibidora 50 , Estrutura Molecular , Pirazóis/síntese química , Pirazóis/química , Pirazóis/farmacocinética , Pirazóis/farmacologia , Ratos , Distribuição TecidualRESUMO
Recent literature has suggested the benefit of selective PPARdelta agonists for the treatment of atherosclerosis and other disease states associated with the metabolic syndrome. Herein we report the synthesis and structure-activity relationships of a series of novel and selective PPARdelta agonists. Our search began with identification of a novel benzothiophene template which was modified by the addition of various thiazolyl, isoxazolyl, and benzyloxy-benzyl moieties. Further elucidation of the SAR led to the identification of benzofuran and indole based templates. During the course of our research, we discovered three new chemical templates with varying degrees of affinity and potency for PPARdelta versus the PPARalpha and PPARgamma subtypes.
Assuntos
Benzofuranos/química , Química Farmacêutica/métodos , Indóis/química , PPAR delta/agonistas , Tiofenos/química , Animais , Benzofuranos/síntese química , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Humanos , Indóis/síntese química , Concentração Inibidora 50 , Ligantes , Modelos Químicos , Relação Estrutura-Atividade , Tiazóis/química , Tiofenos/síntese químicaRESUMO
This manuscript describes the design and synthesis of a series of pyrrole-based inhibitors of HMG-CoA reductase for the treatment of hypercholesterolemia. Analogs were optimized using structure-based design and physical property considerations resulting in the identification of 44, a hepatoselective HMG-CoA reductase inhibitor with excellent acute and chronic efficacy in a pre-clinical animal models.
Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases/química , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Pirróis/química , Pirróis/farmacologia , Animais , Cricetinae , Relação Dose-Resposta a Droga , Desenho de Fármacos , Fluorbenzenos , Hiperlipidemias/tratamento farmacológico , Fígado/efeitos dos fármacos , Modelos Moleculares , Estrutura Molecular , Pirimidinas , Rosuvastatina Cálcica , Relação Estrutura-Atividade , SulfonamidasRESUMO
A systematic investigation of the S3 sub-pocket activity requirements was conducted. It was observed that linear and sterically small side chain substituents are preferred in the S3 sub-pocket for optimal renin inhibition. Polar groups in the S3-sub-pocket were not well tolerated and caused a reduction in renin inhibitory activity. Further, compounds with clog P's < or = 3 demonstrated a dramatic reduction in CYP3A4 inhibitory activity.